-
ASCO2021: Follow the data, eliminate prejudice, and prevent lung cancer in action
Time of Update: 2021-06-16
Studies have confirmed that in addition to smoking, screening in people with risk factors may have an impact, and it is necessary to identify all people who may be at risk .
-
Ann Hematol: ixazomib oral treatment is expected to be a good alternative treatment option for NDMM patients
Time of Update: 2021-06-16
Li jing Li Bao Ixazomib-based Frontline Therapy in patients with newly diagnosed Multiple myeloma in Real-Life Practice Showed the Comparable efficacy and Safety Profile with Those Reported in Clinical Trial: A Multi-Center Study in this message
-
Lancet: Capecitabine beat adjuvant therapy significantly improves the survival prognosis of patients with advanced nasopharyngeal carcinoma
Time of Update: 2021-06-16
Although the proportion of patients with locally advanced nasopharyngeal carcinoma who have achieved complete clinical remission after receiving standard treatment is high, the risk of disease recurrence is still highThis is a multi-center, open-label, parallel-group, randomized controlled Phase 3 trial conducted in 14 hospitals in China.
-
JCO: Prostate cancer patients with high risk of recurrence/death may be consolidated with adjuvant radiotherapy after radical resection
Time of Update: 2021-06-16
After excluding patients with persistently positive prostate-specific antigens, compared with early salvage radiotherapy, adjuvant therapy was associated with a significantly lower risk of all-cause death in patients with pathological dysfunction during radical prostatectomy (0.
-
J Immunother Cancer: Can all cancer patients be treated with the same dose of pembrolizumab?
Time of Update: 2021-06-16
2 years , a one-compartment PK model was generated: body surface area (BSA) and serum albumin had a significant effect on drug clearance (CL; covariate estimates were 1.
-
ASCO 2021: data from monarchE Chinese population: Abesiride combined with endocrine therapy for early breast cancer reduces the risk of recurrence by 34%
Time of Update: 2021-06-16
At this conference, the efficacy and safety data of the monarchE study in the Chinese population were announced.
This result is expected to change the treatment model of early breast cancer in China .
-
ASCO2021: Precision medicine promotes the progress of gastrointestinal cancer treatment
Time of Update: 2021-06-16
The study found that the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab combined with sorafenib can improve overall survival (OS) and Progression-free survival (PFS), which is unprecedented in patients with unresectable hepatocellular carcinoma (HCC) .
-
ASCO2021: Devaruzumab can improve the 5-year survival and progression-free survival of patients with unresectable stage III NSCLC
Time of Update: 2021-06-16
PACIFIC III trials to study the lack of progress after chemotherapy unresectable stage III non-small cell lung cancer ( NSCLC ) patients with at Dewa Lu monoclonal safety and effectiveness of the results made now Dewa Lu mAb significantly increase the total Lifetime (OS) and progression-free survival (PFS) .
-
Nat Commun: FOXO3a-miRNA negative feedback inhibition affects Herceptin resistance in HER2-positive breast cancer
Time of Update: 2021-06-16
Further studies have shown that the expression levels of IGF2 and IRS1 are significantly increased in the tumor tissue and blood of breast cancer patients who have a poor response to the Herceptin treatment regimen .
-
Blood: TLR9, a new therapeutic target for chronic lymphocytic leukemia!
Time of Update: 2021-06-16
Center point:Center point:The expression of TLR9, its agonist, and free plasma DNA are all related to the accelerated metastasis and poor prognosis of CLL .
The expression of TLR9, its agonist, and free plasma DNA are all related to the accelerated metastasis and poor prognosis of CLL .
-
2021 ASCO Voice of China in the field of breast cancer!
Time of Update: 2021-06-16
In this randomized, double-blind, phase 3 trial, patients with HR+/HER2− locally advanced or metastatic breast cancer (pts) were recruited who had relapsed or progressed from previous endocrine therapy .
Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for hormone receptor-positive and HER2-positive metastatic breast cancer: sysucc-002 randomized clinical trial
-
Research progress of exosomes in tumor immune microenvironment
Time of Update: 2021-06-16
Tumor Tumor-derived EVs recruit and induce immunosuppressive cells (including regulatory B cells (Breg), regulatory T cells (Treg), myeloid-derived suppressor cells (MDSCs), M2-like tumor-associated macrophages (TAMs) and medium The differentiation of sex granulocytes) to exert immunosuppressive activity.
-
2021 ASCO: The Voice of China in the Field of Hepatocellular Carcinoma
Time of Update: 2021-06-16
Therefore, this study is the first real-world data on the timing of the combination of lenvatinib and TACE in the treatment of patients with unresectable HCC .
Real-world data on the timing of the combination of lenvatinib and TACE in the treatment of patients with unresectable HCC .
-
Extracellular miR-31-5p derived from hypoxic tumor promotes lung adenocarcinoma metastasis through EMT and activation of MEKERK signaling pathway
Time of Update: 2021-06-16
Recently, a researcher from the Department of Thoracic Surgery of Union Hospital of Fujian Medical University published in the Journal of Experimental & Clinical Cancer Research titled "Hypoxic tumor-derived exosomal miR-31-5p promotes lung adenocarcinoma metastasis by negatively regulating SATB2-reversed EMT and activating MEK/ERK signaling" article .
-
NEJM: Sotorasib treatment of KRASp.G12C mutant advanced non-small cell lung cancer Phase II clinical data is gratifying
Time of Update: 2021-06-16
Progression-free survival after Sotorasib treatment, overall survival dataStudies believe that Sotorasib has shown good therapeutic effects and good safety in KRASp. G12C mutant non-small cell lung cancer patients who have previously received platinum chemotherapy or immunotherapy .
-
Initiation of triple immunization program for PD-1/L1 monoclonal antibody treatment of drug-resistant prenabulin...
Time of Update: 2021-06-12
It is reported that this trial was initiated by researchers to evaluate the safety and tolerability of pranabulin, PD-1/PD-L1 antibody and radiotherapy triple therapy in patients with 7 types of metastatic or locally advanced cancer Sex.
-
May 2021 Drug Registration Review and Approval Report
Time of Update: 2021-06-12
There are a total of 118 acceptance numbers for new applications of category 1 innovative drugs, including domestic and imported varieties.
There are a total of 118 acceptance numbers for new applications of category 1 innovative drugs, including domestic and imported varieties.
-
Boan Bio-Boyounuo® (bevacizumab injection) is officially listed as a patient aid item...
Time of Update: 2021-06-12
Its original drug is approved worldwide for the treatment of non-small cell lung cancer, colorectal cancer, glioblastoma, renal cell carcinoma, and cervical cancer , Ovarian cancer and many other solid tumors, the remarkable curative effect and good safety have been widely recognized by doctors and patients in long-term clinical application.
-
ASCO annual meeting grand opening!
Time of Update: 2021-06-12
According to reports, the RATIONALE 302 study is a randomized, open, multi-center, global phase 3 clinical trial designed to evaluate tislelizumab versus chemotherapy selected by investigators as the second-line treatment for patients with advanced or metastatic esophageal squamous cell carcinoma Effectiveness and safety.
-
Innovate, gather strength and practice to achieve the future-2021 Chinese Academic Year of Clinical Pharmacy...
Time of Update: 2021-06-12
Gathering in the clouds, composing a glorious chapter together. On June 5, 2021, sponsored by the Chinese Hospital Association and the Institute of Hospital Management of the National Health and Hea
